Dr. Kris on Dacomitinib in EGFR-Positive Lung Cancer
Mark G. Kris, MD
Published Online: Wednesday, December 12, 2012
Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, discusses the initial trials studying dacomitinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), in patients with EGFR-mutant lung cancers.
Kris explains that dacomitinib was first studied in hopes that a greater, potentially permanent, tumor shrinkage would occur. A phase II study compared dacomitinib to reversible TKIs such as gefitinib and erlotinib as a first-line treatment for patients with lung cancers. The partial response rate was 74% among patients with EGFR deletions at exons 19 and 21. At one year, progression-free survival (PFS) rate was 77% and median PFS was 17 months.
Dacomitib may be as effective as gefitinib in terms of degree and length of tumor shrinkage, Kris believes.
In this segment, panelists discuss the number of early-phase clinical trials that have demonstrated impressive efficacy for next-generation ALK and EGFR inhibitors for patients with non-small cell lung cancer.
Panelists discuss the frontline treatment of patients with unresectable metastatic colorectal cancer, which has become a more challenging decision in recent years as a result of studies focused on RAS mutations.